Observational study of a Chinese herbal method for diabetic kidney disease
Follows adults with diabetic kidney disease to see if a herbal method delays kidney failure.
Plain-language title generated from the registry record
Registry title: YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1
Key facts
- Where
- Beijing, Changchun, Guangzhou, and Tianjin, ChinaSee the 5 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetic kidney disease and a traditional Chinese medicine pattern called qi deficiency and collateral stasis, whose kidneys still work above a set level.
- Age
- 18 to 80 years
- Sex
- Men and women can join.
- Disease stage
- Type 2 diabetic kidney disease with eGFR above 15 ml/(min·1.73m2), and qi deficiency and collateral stasis syndrome in traditional Chinese medicine.
- Biomarker or test result
- HbA1c between 7-10 % (53–86 mmol/mol). Blood pressure 160/100 mmHg or lower.
Main reasons for not taking part
- Other clear kidney diseases, such as polycystic kidney disease, glomerulonephritis or kidney tumor
- History of repeated urinary or genital tract infection
- Serious heart, brain, digestive, lung, urinary or immune diseases, or mental illness
- Pregnant, breastfeeding, or planning a pregnancy
- Type 1 diabetes, or cancer treated with radiotherapy, chemotherapy or targeted therapy
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07032116, who can take part
Where in China
- Dongzhimen Hospital of BeijingUniversity of Chinese MedicineBeijing, ChinaNo longer taking part
- Guang'anmen Hospital，China Academy of Chinese Medical SciencescancelBeijing, ChinaNo longer taking part
- The Affiliated Hospital to ChangChun University of Chinese MedicinecancelChangchun, ChinaNo longer taking part
- the First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou, ChinaNo longer taking part
- Tianjin Medical University Chu Hsien-I Memorial HospitalTianjin, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Liu Hongfang
- Trial code
- NCT07032116
- Record updated
- 22 June 2025
- Original description
In order to reduce the clinical demand for kidney dialysis rate of Diabetic Kidney Disease（DKD） patients, a bidirectional cohort study of 4472 patients with DKD (Qi deficiency and collateral stasis syndrome) was carried out based on a preliminary DKD cohort of 13,000 patients. The exposure factor was supplementing and reducing the kidney turbidity-Huoxue Tongluo method represented by the addition and subversion of Shenzhuo prescription, and the incidence of end-stage renal disease was the main therapeutic index. Follow-up was conducted for 2 yearsRead full original descriptionShow less
Evidence-based Evaluation of Yiqi Jiangzhuo Huoxue Tongluo Method in Delaying the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study 1
In order to reduce the clinical demand for kidney dialysis rate of Diabetic Kidney Disease（DKD） patients, a bidirectional cohort study of 4472 patients with DKD (Qi deficiency and collateral stasis syndrome) was carried out based on a preliminary DKD cohort of 13,000 patients. The exposure factor was supplementing and reducing the kidney turbidity-Huoxue Tongluo method represented by the addition and subversion of Shenzhuo prescription, and the incidence of end-stage renal disease was the main therapeutic index. Follow-up was conducted for 2 years
Inclusion: 1 in line with Western medicine diagnostic criteria for type 2 diabetic kidney disease ; 2 18-80 years old, regardless of gender ; 3 eGFR > 15ml / ( min · 1.73m2 ) ; the eGFR was calculated according to the chronic kidney disease epidemiology collaboration equation ( CKD-EPI ); 4 In line with the diagnostic criteria of qi deficiency and collateral stasis syndrome in traditional Chinese medicine ; 5glycosylated hemoglobin ( HbA1c ) between 7-10 % ; 6 blood pressure ≤ 160 / 100mmHg ; 7 to sign the informed consent .
Exclusion: 6 Tumor patients undergoing radiotherapy, chemotherapy or targeted therapy; 1 combined with other clear renal diseases, such as polycystic kidney disease, glomerulonephritis, renal tumor, etc. ; 2 patients with a history of recurrent genitourinary tract infection ; 3 combined with cardiovascular and cerebrovascular, digestive, respiratory, urinary, immune system serious diseases or mental diseases ; 5 Patients with type 1 diabetes; 4 currently in pregnancy, lactation, or pregnancy plan women .